Physician profile
Bryan D Blake
NPI 1316930118
$13,661.46
in general payments reported to CMS, 2019-2025
39 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $1,822 · 2021: $2,884 · 2022: $2,439 · 2023: $2,486 · 2024: $1,395 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,992 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,992.49 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,527.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,010.67 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $1,358.30 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $827.08 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $785.17 | 2021-2025 | |
| Lilly USA, LLC | $688.39 | 2019-2024 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $503.63 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.60 | 2020-2025 | Jardiance |
| Dexcom, INC. | $393.67 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $372.33 | 2019-2023 | |
| Esperion Therapeutics, INC. | $354.89 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $353.29 | 2021-2024 | Livalo, Seglentis |
| Vanda Pharmaceuticals INC. | $311.31 | 2021-2023 | Hetlioz |
| Eisai INC. | $293.64 | 2020-2022 | |
| Glaxosmithkline, LLC. | $273.93 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $245.60 | 2022-2024 | Caplyta |
| Abbvie INC. | $234.28 | 2021-2024 | Vraylar |
| Exact Sciences Corporation | $198.09 | 2023-2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $191.98 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Merck Sharp & Dohme LLC | $177.83 | 2019-2023 | Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $167.30 | 2020-2021 | |
| Global Blood Therapeutics, INC. | $166.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $165.69 | 2023-2024 | Quviviq |
| Amgen INC. | $104.09 | 2019-2023 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $97.13 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $76.52 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.12 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $60.13 | 2019-2021 | |
| Kyowa Kirin, INC. | $44.61 | 2024-2025 | Crysvita |
| Sumitomo Pharma America, INC. | $39.61 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $28.19 | 2021-2023 | Onzetra Xsail, Contrave |
| Inspire Medical Systems, INC. | $27.67 | 2024 | Inspire |
| Horizon Therapeutics Plc | $21.71 | 2020 | |
| Xeris Pharmaceuticals, INC. | $20.45 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.41 | 2022 | |
| Travere Therapeutics, INC. | $15.37 | 2023 | Cholbam |
| Allergan, INC. | $14.99 | 2020 | |
| Atland Pharmaceuticals, LLC | $13.60 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Janssen Pharmaceuticals, INC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.